HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Monoclonal antibody therapy for malignant lymphoma].

Abstract
The treatment options for patients with malignant lymphoma have been substantially enriched by the development of B-cell-specific monoclonal antibodies. One of the reasons for the attractiveness of this approach is the different mode of action of these antibodies compared to chemotherapy: they can exert tumor-suppressive effects by at least three major mechanisms: an intrinsic cytotoxic activity, antibody-dependent cellular cytotoxicity (ADCC), and activation of complement-dependent cytolysis (CDC). These monoclonal antibodies can be applied in an unconjugated form or as a carrier of cytotoxic drugs or radioisotopes. The chimeric anti-CD20 antibody rituximab has a direct anti-lymphoma activity, and is highly active in indolent and aggressive lymphoma, in particular in combination with chemotherapy. The anti-CD52 antibody alemtuzumab is effective in the treatment of patients with chronic lymphocytic leukemia (CLL). Another attractive approach is to link anti-CD20 antibodies to radioisotopes, thereby exploiting the radiosensitivity of malignant lymphomas: encouraging results were already presented for the yttrium-90-((90)Y-)labeled anti-CD20 antibody ibritumomab tiuxetan as well as for the iodine-131-((131)I-)labeled anti-CD20 antibody tositumomab.
AuthorsChristian Buske, Martin Dreyling, Michael Unterhalt, Wolfgang Hiddemann
JournalMedizinische Klinik (Munich, Germany : 1983) (Med Klin (Munich)) Vol. 100 Issue 1 Pg. 14-24 (Jan 15 2005) ISSN: 0723-5003 [Print] Germany
Vernacular TitleAntikörpertherapie maligner Lymphome.
PMID15654538 (Publication Type: Comparative Study, English Abstract, Journal Article, Review)
Chemical References
  • Antibodies, Bispecific
  • Antibodies, Monoclonal
Topics
  • Antibodies, Bispecific (immunology, therapeutic use)
  • Antibodies, Monoclonal (immunology, therapeutic use)
  • Antibody-Dependent Cell Cytotoxicity (immunology)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Follow-Up Studies
  • Humans
  • Lymphoma, B-Cell (drug therapy)
  • Lymphoma, Non-Hodgkin (drug therapy, immunology)
  • Radioimmunotherapy
  • Remission Induction
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: